Blueprint Medicines has been granted a patent for crystalline forms of Compound (I) and its pharmaceutically acceptable salts. The patent includes methods for treating gastrointestinal stromal tumors associated with oncogenic KIT and PDGFRA alterations using these compounds. GlobalData’s report on Blueprint Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Blueprint Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Blueprint Medicines's grant share as of July 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of gastrointestinal stromal tumors using compound (i)
The granted patent US12060354B2 outlines methods for treating gastrointestinal stromal tumors (GIST) and acute myeloid leukemia (AML) using a specific crystalline form of a compound, referred to as Crystalline Form A of Compound (I). The claims specify that the treatment involves administering a therapeutically effective amount of this compound to patients diagnosed with these conditions. Notably, the patent highlights the relevance of specific mutations in the PDGFRa gene, such as exon 18 and D842V mutations, in the context of GIST treatment.
Additionally, the patent provides detailed characterization of Crystalline Form A through its X-ray powder diffractogram and differential scanning calorimetry (DSC) thermogram. The X-ray powder diffractogram is defined by multiple peaks at specified 2? angles, which serve as a fingerprint for the crystalline form, ensuring its identification and quality. The DSC thermogram indicates an endothermic event at temperatures ranging from 194°C to 195°C, further confirming the compound's unique properties. These specifications are critical for the reproducibility and efficacy of the treatment methods described in the patent.
To know more about GlobalData’s detailed insights on Blueprint Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
